Bill Summary
The "Restoring Confidence in the World Anti-Doping Agency Act of 2025" seeks to amend the Office of National Drug Control Policy Reauthorization Act of 2006, focusing on enhancing the governance and representation of the United States within the World Anti-Doping Agency (WADA). Key provisions include:
1. **Definition Updates**: The bill clarifies terminology related to the United States Olympic and Paralympic Committee and introduces a new definition for "independent athlete."
2. **Enhanced Oversight**: It grants the Office of National Drug Control Policy (ONDCP) specific authority to ensure that WADA establishes a credible and independent governance model that fairly represents the U.S. This includes the implementation of conflict-of-interest policies and ensuring that independent athletes have decision-making roles.
3. **Accountability Measures**: The ONDCP is tasked with evaluating WADA's governance within 90 days of enactment and determining whether it meets the established criteria. If it does not, the ONDCP can withhold membership dues and report on barriers to U.S. participation.
4. **Collaboration with Stakeholders**: The ONDCP must work in consultation with the U.S. Anti-Doping Agency, the U.S. Olympic and Paralympic Committee, and the Team USA Athletes' Commission to ensure compliance with these objectives.
Overall, the legislation aims to strengthen U.S. representation in international anti-doping governance and promote fair practices in sports.
Possible Impacts
Here are three examples of how the "Restoring Confidence in the World Anti-Doping Agency Act of 2025" could affect people:
1. **Athlete Representation and Decision-Making**:
The legislation emphasizes the need for independent athletes to have decision-making roles within the governance structure of the World Anti-Doping Agency (WADA). This could empower athletes by giving them a voice in the policies that affect them, leading to a more equitable representation of their interests. Athletes may feel more confident that their concerns regarding doping regulations and governance are being addressed, potentially enhancing their trust in the anti-doping system.
2. **Increased Accountability of WADA**:
The act requires the Office of National Drug Control Policy (ONDCP) to assess whether WADA is operating with a credible governance model and implementing necessary reforms. If WADA fails to meet these standards, the ONDCP may withhold dues, which could pressure WADA to improve its practices. This increased scrutiny may lead to a more transparent and accountable anti-doping framework, benefiting athletes who seek fairness and integrity in sports.
3. **Impact on Funding and Resources for Anti-Doping Efforts**:
The legislation allows for the voluntary withholding of membership dues to WADA if the agency does not meet governance criteria. This could impact the funding and resources available for anti-doping efforts globally. If WADA faces financial challenges due to reduced funding, it may struggle to implement effective doping control measures, which could ultimately affect the integrity of sports and the health of athletes who rely on a fair and clean competitive environment.
[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 693 Introduced in House (IH)]
<DOC>
119th CONGRESS
1st Session
H. R. 693
To amend the Office of National Drug Control Policy Reauthorization Act
of 2006 to modify the authority of the Office of National Drug Control
Policy with respect to the World Anti-Doping Agency, and for other
purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
January 23, 2025
Mr. Moolenaar (for himself and Mr. Krishnamoorthi) introduced the
following bill; which was referred to the Committee on Energy and
Commerce
_______________________________________________________________________
A BILL
To amend the Office of National Drug Control Policy Reauthorization Act
of 2006 to modify the authority of the Office of National Drug Control
Policy with respect to the World Anti-Doping Agency, and for other
purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Restoring Confidence in the World
Anti-Doping Agency Act of 2025''.
SEC. 2. AUTHORITY OF NATIONAL DRUG CONTROL POLICY WITH RESPECT TO THE
WORLD ANTI-DOPING AGENCY.
Section 701 of the Office of National Drug Control Policy
Reauthorization Act of 2006 (21 U.S.C. 2001) is amended--
(1) in subsection (a)--
(A) by amending paragraph (1) to read as follows:
``(1) United states olympic and paralympic committee.--The
term `United States Olympic and Paralympic Committee' means the
organization established by chapter 2205 of title 36, United
States Code.'';
(B) in paragraph (3), by striking ``(36 U.S.C.
22501(b)(1))'' and inserting ``(36 U.S.C.
220501(b)(1))'';
(C) by redesignating paragraphs (1) and (3) as
paragraphs (4) and (1), respectively, and moving the
paragraphs so as to appear in numeric order; and
(D) by inserting after paragraph (2) the following:
``(3) Independent athlete.--The term `independent athlete'
means an Olympic or Paralympic athlete who does not serve, in
any capacity--
``(A) on the International Olympic Committee;
``(B) on the International Paralympic Committee;
``(C) at an international sports federation
recognized by the International Olympic Committee or
the International Paralympic Committee;
``(D) on the United States Olympic and Paralympic
Committee; or
``(E) at the World Anti-Doping Agency.'';
(2) in subsection (b)--
(A) by striking ``United States Olympic Committee''
each place it appears and inserting ``United States
Olympic and Paralympic Committee'';
(B) in paragraph (5), by striking the period at the
end and inserting ``; and''; and
(C) by adding at the end the following:
``(6) carry out responsibilities with respect to the World
Anti-Doping Agency, as described in subsection (d).''; and
(3) by adding at the end the following:
``(d) Authority With Respect to the World Anti-Doping Agency.--
``(1) In general.--The Office of National Drug Control
Policy, in consultation with the United States Anti-Doping
Agency, the United States Olympic and Paralympic Committee, and
the Team USA Athletes' Commission, shall--
``(A) use all available tools to ensure that--
``(i) the World Anti-Doping Agency has a
credible and independent governance model that
provides for fair representation of the United
States;
``(ii) the World Anti-Doping Agency fully
implements all governance reforms, including a
proper conflict-of-interest policy for all
members of the Executive Committee, the
Foundation Board, and all relevant expert
advisory groups, standing committees, permanent
special committees, and working groups of the
World Anti-Doping Agency; and
``(iii) independent athletes from the
United States and other democratic countries,
or representatives of such athletes, have
decision-making roles on the Executive
Committee and the Foundation Board, and in all
relevant expert advisory groups, standing
committees, permanent special committees, and
working groups, of the World Anti-Doping
Agency;
``(B) demonstrate leadership within the global
community;
``(C) have strict standards that work toward
countering doping in every form, including by
countering systemic fraud through doping involving--
``(i) governmental law enforcement,
intelligence, or anti-doping institutions;
``(ii) sporting organizations; or
``(iii) athlete support personnel; and
``(D) work collaboratively with democratic
countries.
``(2) Determination.--
``(A) In general.--Not later than 90 days after the
date of the enactment of this subsection, the Office of
National Drug Control Policy, in consultation with the
United States Anti-Doping Agency, the United States
Olympic and Paralympic Committee, and the Team USA
Athletes' Commission, shall make a determination as to
whether the World Anti-Doping Agency--
``(i) has a credible and independent
governance model that provides for fair
representation of the United States;
``(ii) fully implements all governance
reforms, including a proper conflict-of-
interest policy described in paragraph
(1)(A)(ii); and
``(iii) allows independent athletes from
the United States and other democratic
countries, or representatives of such athletes,
to have decision-making roles on the Executive
Committee and the Foundation Board, and in all
relevant expert advisory groups, standing
committees, permanent special committees, and
working groups, of the World Anti-Doping
Agency.
``(B) Accountability.--In the case of a
determination under subparagraph (A) that the World
Anti-Doping Agency does not have such a governance
model, has not fully implemented such governance
reforms, or has not allowed decision-making roles
described in clause (iii) of that subparagraph, the
Office of National Drug Control Policy, in consultation
with the United States Anti-Doping Agency, the United
States Olympic and Paralympic Committee, and the Team
USA Athletes' Commission, shall--
``(i) use all available tools to ensure
that the United States has fair representation
in the World Anti-Doping Agency, including--
``(I) on the Executive Committee;
``(II) on the Foundation Board; and
``(III) in all relevant expert
advisory groups, standing committees,
permanent special committees, and
working groups of the World Anti-Doping
Agency; and
``(ii) not later than 180 days after the
date on which the determination under
subparagraph (A) is made, issue a report that
describes the barriers to participation and
fair representation of the United States on the
Executive Committee, the Foundation Board, and
all relevant expert advisory groups, standing
committees, permanent special committees, and
working groups of the World Anti-Doping Agency.
``(3) Voluntary nonpayment of dues.--
``(A) In general.--In the case of a determination
under paragraph (2)(A) that the World Anti-Doping
Agency does not have a governance model that provides
for fair representation of the United States, has not
fully implemented governance reforms, or has not
allowed decision-making roles described in clause (iii)
of that subparagraph, the Office of National Drug
Control Policy, in consultation with the appropriate
committees of Congress, may voluntarily withhold up to
the full amount of membership dues to the World Anti-
Doping Agency.
``(B) Appropriate committees of congress defined.--
In this paragraph, the term `appropriate committees of
Congress' means--
``(i) the Subcommittee on Consumer
Protection, Product Safety, and Data Security
of the Committee on Commerce, Science, and
Transportation of the Senate (or a successor
subcommittee);
``(ii) the Subcommittee on Financial
Services and General Government of the
Committee on Appropriations of the Senate (or a
successor subcommittee);
``(iii) the Subcommittee on Oversight and
Investigations of the Committee on Energy and
Commerce of the House of Representatives (or a
successor subcommittee); and
``(iv) the Subcommittee on Financial
Services and General Government of the
Committee on Appropriations of the House of
Representatives (or a successor subcommittee).
``(4) Spending plan.--Not later than 30 days before the
Office of National Drug Control Policy obligates funds to the
World Anti-Doping Agency, the Office of National Drug Control
Policy shall submit to the Committee on Appropriations of the
Senate and the Committee on Appropriations of the House of
Representatives a spending plan and explanation of proposed
uses of such funds.''.
<all>